Investor Growth Capital and CapMan invest in Neoventa Medical

Investor Growth Capital and CapMan invest in Neoventa Medical AB, a Swedish medical technology company within the area of fetal monitoring. Following these investments, CapMan and Investor Growth Capital will each have an approximately 30% stake in Neoventa. The majority of the other shares will be retained by SEB Företagsinvest. The new shareholder structure will together secure a total capital injection of SEK 75 million that will finance the next phase of growth for Neoventa with a focus on the US market.

Read more

Neoventa introduces unique fetal heart monitor to the U.S. market

The U.S. Food and Drug Admistration (FDA) has approved the STAN® S31 Fetal heart monitor Pre-Market Approval (PMA) application. STAN from Neoventa Medical is the first fetal monitor proven to reduce the risk of brain injury during labor.

Read more

FDA Advisory Panel Unanimously Recommends Approval of the STAN Fetal heart monitor from Neoventa Medical

The U.S. Food and Drug Administration’s (FDA) Obstetrics and Gynecology Advisory Panel voted Thursday to recommend approval of the STAN® S31 Fetal heart monitor Pre-Market Approval (PMA) application. STAN helps clinicians identify babies at risk due to oxygen deficiency during labor. It also reduces the number of unnecessary operative interventions.

Read more
Page 10 of 10 «...678910

# #